Vertex announces u.s. fda acceptance of supplemental new drug application for trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 6 through 11 with certain mutations

Boston--(business wire)-- #cf--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the u.s. food and drug administration (fda) has accepted its supplemental new drug application (snda) to expand the use of trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children ages 6 through 11 years old who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene or a mutation in the cftr gene that is responsive based on in
VRTX Ratings Summary
VRTX Quant Ranking